Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
RANI
$1.31
$
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Next Earnings
2026-02-25
Beta
0.43
Average Volume
Market Cap
Last Dividend
CIK
0001856725
ISIN
US7530181004
CUSIP
753018100
CEO
Talat Imran
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
105
IPO Date
2021-07-30
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of “Moderate Buy” from Brokerages | Rani Therapeutics Holdings, Inc. (NASDAQ: RANI - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target | Defense World | 2026-02-22 03:12:56 |
| Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer | SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. | GlobeNewsWire | 2026-01-28 07:00:00 |
| Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen | - A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus subcutaneous injection - SAN JOSE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation of a Phase 1 clinical trial to evaluate the safety, tolerability, bioavailability, and pharmacokinetics and pharmacodynamics of single and multiple doses of RT-114, an orally administered RaniPill® capsule containing a GLP-1/GLP-2 dual agonist, PG-102, for the treatment of obesity. | GlobeNewsWire | 2026-01-08 07:00:00 |
| Rani Therapeutics (NASDAQ:RANI) Stock Price Down 2.2% – What’s Next? | Rani Therapeutics Holdings, Inc. (NASDAQ: RANI - Get Free Report)'s share price fell 2.2% during mid-day trading on Tuesday. The stock traded as low as $1.35 and last traded at $1.35. 1,356,778 shares changed hands during mid-day trading, a decline of 47% from the average session volume of 2,566,240 shares. The stock had previously closed | Defense World | 2025-12-31 01:32:58 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G | 2026-02-12 | 2026-02-12 | View Filing |
| SC 13G | 2026-01-30 | 2026-01-30 | View Filing |
| 8-K | 2026-01-02 | 2026-01-02 | View Filing |
| DEF 14C | 2025-12-05 | 2025-12-05 | View Filing |
| EFFECT | 2025-12-03 | 2025-12-04 | View Filing |
| 424B5 | 2025-12-03 | 2025-12-03 | View Filing |
| PRE 14C | 2025-11-25 | 2025-11-25 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| D | 2025-11-10 | 2025-11-07 | View Filing |
| S-3 | 2025-11-07 | 2025-11-07 | View Filing |
| 10-Q | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-06 | 2025-11-06 | View Filing |
| SC 13D | 2025-10-30 | 2025-10-30 | View Filing |
| SC 13G | 2025-10-30 | 2025-10-30 | View Filing |
| 4 | 2025-10-30 | 2025-10-30 | View Filing |
| 3 | 2025-10-30 | 2025-10-30 | View Filing |
| SC 13D/A | 2025-10-27 | 2025-10-27 | View Filing |
| 4 | 2025-10-27 | 2025-10-27 | View Filing |
| 3 | 2025-10-27 | 2025-10-27 | View Filing |
| 4 | 2025-10-27 | 2025-10-27 | View Filing |
| 8-K | 2025-10-27 | 2025-10-27 | View Filing |
| SC 13G | 2025-10-23 | 2025-10-23 | View Filing |
| SC 13D/A | 2025-10-22 | 2025-10-22 | View Filing |
| 4 | 2025-10-22 | 2025-10-22 | View Filing |
| 8-K | 2025-10-17 | 2025-10-17 | View Filing |
| EFFECT | 2025-08-15 | 2025-08-15 | View Filing |
| SC 13G | 2025-08-14 | 2025-08-14 | View Filing |
| S-3 | 2025-08-08 | 2025-08-08 | View Filing |
| 10-Q | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-08-05 | 2025-08-05 | View Filing |
| SC 13G/A | 2025-07-23 | 2025-07-23 | View Filing |
| SC 13G | 2025-07-17 | 2025-07-17 | View Filing |
| 8-K | 2025-07-16 | 2025-07-16 | View Filing |
| 424B5 | 2025-07-16 | 2025-07-16 | View Filing |
| EFFECT | 2025-07-14 | 2025-07-14 | View Filing |
| 424B5 | 2025-07-11 | 2025-07-11 | View Filing |
| DEF 14C | 2025-07-10 | 2025-07-10 | View Filing |
| S-3 | 2025-07-03 | 2025-07-03 | View Filing |
| PRE 14C | 2025-06-30 | 2025-06-30 | View Filing |
| 8-K | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 8-K | 2025-05-29 | 2025-05-29 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 8-K | 2025-05-20 | 2025-05-20 | View Filing |
| 424B5 | 2025-05-19 | 2025-05-16 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-06 | 2025-05-06 | View Filing |
| DEFA14A | 2025-04-30 | 2025-04-30 | View Filing |
| 8-K | 2025-04-30 | 2025-04-30 | View Filing |
| ARS | 2025-04-16 | 2025-04-16 | View Filing |
| DEFA14A | 2025-04-16 | 2025-04-16 | View Filing |
| DEF 14A | 2025-04-16 | 2025-04-16 | View Filing |
| 8-K | 2025-04-09 | 2025-04-09 | View Filing |
| S-8 | 2025-03-31 | 2025-03-31 | View Filing |
| 10-K | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-03-31 | 2025-03-31 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-16 | 2024-12-16 | View Filing |
| 4 | 2024-12-10 | 2024-12-10 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13D/A | 2024-10-17 | 2024-10-17 | View Filing |
| 4 | 2024-10-17 | 2024-10-17 | View Filing |
| 8-K | 2024-10-16 | 2024-10-16 | View Filing |
| 424B5 | 2024-10-16 | 2024-10-16 | View Filing |
| 8-K | 2024-09-11 | 2024-09-11 | View Filing |
| 10-Q | 2024-08-06 | 2024-08-06 | View Filing |
| 8-K | 2024-08-06 | 2024-08-06 | View Filing |
| 8-K | 2024-07-23 | 2024-07-23 | View Filing |
| 424B5 | 2024-07-23 | 2024-07-23 | View Filing |
| 8-K | 2024-07-12 | 2024-07-12 | View Filing |
| 8-K | 2024-06-24 | 2024-06-24 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 8-K | 2024-05-30 | 2024-05-30 | View Filing |
| 10-Q | 2024-05-06 | 2024-05-06 | View Filing |
| 8-K | 2024-05-06 | 2024-05-06 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Swarm Intelligence Strategy | 20.92% | 0.98 | 39 | 0.49 | 0.32 | 21.98 |
| Super Trend Strategy | 10.97% | 1 | 39 | 0.72 | 0.53 | 7.06 |
| Super Trend Strategy | 10.34% | 1.05 | 39 | 0.28 | 0.23 | 11.39 |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | x | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | x |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | x | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |